<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03644667</url>
  </required_header>
  <id_info>
    <org_study_id>DAIT RTB-004</org_study_id>
    <secondary_id>ALL IN</secondary_id>
    <secondary_id>U01AI136816</secondary_id>
    <nct_id>NCT03644667</nct_id>
  </id_info>
  <brief_title>Tocilizumab in Cardiac Transplantation</brief_title>
  <official_title>Targeting Inflammation and Alloimmunity in Heart Transplant Recipients With Tocilizumab (RTB-004)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>National Institute of Allergy and Infectious Diseases (NIAID)</agency>
      <agency_class>NIH</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>PPD</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>National Institute of Allergy and Infectious Diseases (NIAID)</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this research study is to see if a study drug called Tocilizumab will, when&#xD;
      given with standard anti-rejection medicines, lead to better heart transplantation outcomes&#xD;
      at 1 year after the transplant. Specifically, the investigators will evaluate whether taking&#xD;
      tocilizumab leads to less rejection, less development of unwanted antibodies, and better&#xD;
      heart function.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a prospective, multi-center phase 2 clinical trial in which 200 primary heart&#xD;
      transplant recipients will be randomized (1:1) to receive either tocilizumab (Actemra®) or&#xD;
      placebo (normal saline) plus standard triple maintenance immunosuppression. Investigators&#xD;
      will recruit primary heart transplant recipients from 14 participating centers. Subjects will&#xD;
      be screened, consented, and enrolled while on the United Network for Organ Sharing (UNOS)&#xD;
      wait list. When the recipient has received the transplant and is deemed hemodynamically&#xD;
      stable, randomization will occur.&#xD;
&#xD;
      Study duration: The study duration will be approximately 4 years. There will be a 36-month&#xD;
      accrual period, and participants will be followed for a minimum 12-month, and a maximum 24&#xD;
      months after heart transplantation.&#xD;
&#xD;
      *** IMPORTANT NOTICE: *** The National Institute of Allergy and Infectious Diseases does not&#xD;
      recommend the discontinuation of immunosuppressive therapy for recipients of cell, organ, or&#xD;
      tissue transplants outside of physician-directed, controlled clinical studies.&#xD;
      Discontinuation of prescribed immunosuppressive therapy can result in serious health&#xD;
      consequences and should only be performed in certain rare circumstances, upon the&#xD;
      recommendation and with the guidance of your health care provider.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">December 20, 2018</start_date>
  <completion_date type="Anticipated">August 2023</completion_date>
  <primary_completion_date type="Anticipated">August 2022</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Care Provider, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Proportion of Participants Positive for Event of dnDSA, ACR, AMR, Hemodynamic Compromise, Death or Re-Transplantation - By Treatment Group</measure>
    <time_frame>From transplant through 12 months post transplant surgery (12 months)</time_frame>
    <description>This outcome is defined by a composite 1 year post-transplant endpoint of:&#xD;
detection of de novo donor-specific antibodies (dnDSA) (Core Laboratory),&#xD;
acute cellular rejection (ACR) ≥ ISHLT 2R rejection (Core Laboratory),&#xD;
antibody mediated rejection (AMR) ≥ ISHLT AMR 1 (Core Laboratory),&#xD;
hemodynamic compromise rejection in the absence of a biopsy or histological rejection,&#xD;
death, or&#xD;
re-transplantation.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Freedom of Detection of de Novo Donor-Specific Antibodies (dnDSA) - by Treatment Group</measure>
    <time_frame>From transplant through 12 months post transplant surgery (12 months)</time_frame>
    <description>A comparison by treatment group of the incidence of freedom from development of de novo donor-specific antibodies (dnDSA). dnDSA is a newly developed alloantibody that is against the donor organ.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Freedom from Acute Cellular Rejection (ACR) ≥ International Society of Heart and Lung Transplantation (ISHLT) 2R Rejection - by Treatment Group</measure>
    <time_frame>From transplant through 12 months post transplant surgery (12 months)</time_frame>
    <description>A comparison by treatment group of the incidence of freedom from development of acute cellular rejection ≥2R (Reference: International Society of Heart and Lung Transplantation [ISHLT] acute cellular rejection-grade 2R or greater severity).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Freedom from Antibody Mediated Rejection (AMR) ≥ International Society of Heart and Lung Transplantation (ISHLT) AMR 1 - by Treatment Group</measure>
    <time_frame>From transplant through 12 months post transplant surgery (12 months)</time_frame>
    <description>A comparison by treatment group of the incidence of freedom from development of antibody-mediated rejection defined as ISHLT grade AMR 1 or greater severity.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Freedom from Hemodynamic Compromise Rejection in the Absence of a Biopsy or Histological Rejection - by Treatment Group</measure>
    <time_frame>From transplant through 12 months post transplant surgery (12 months)</time_frame>
    <description>A comparison by treatment group of the incidence of freedom from development of hemodynamic compromise (HDC).&#xD;
Hemodynamic compromise is defined by:&#xD;
- Need for inotropic agents due to a Cardiac Index (CI) &lt;2.0 L/min/m^2 or a 25% decrease from baseline, in addition to one of the following:&#xD;
ejection fraction of &lt;40% or a 20% decrease from baseline, and the need for inotropic agents OR&#xD;
fractional shortening of &lt;20% or a 25% decrease from baseline, and the need for inotropic agents.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Freedom from Any-Treated Rejection - by Treatment Group</measure>
    <time_frame>From transplant through 12 months post transplant surgery (12 months)</time_frame>
    <description>A comparison by treatment group of the incidence of freedom from development of episode of rejection requiring treatment. Reference: Acute cellular rejection as defined by the 2004 International Society of Heart and Lung Transplantation (ISHLT) grading scale.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Freedom from Acute Cellular Rejection (ACR) ≥ International Society of Heart and Lung Transplantation (ISHLT) 2R Per Patient - by Treatment Group</measure>
    <time_frame>From transplant through 12 months post transplant surgery (12 months)</time_frame>
    <description>A comparison by treatment group of the incidence of freedom from acute cellular rejection (ACR) ≥ ISHLT 2R rejection. Reference: 2004 International Society of Heart and Lung Transplantation [ISHLT [ grading scale).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Freedom from Antibody Mediated Rejection (AMR) (≥ International Society of Heart and Lung Transplantation (ISHLT) AMR 1) Per Participant - by Treatment Group</measure>
    <time_frame>From transplant through 12 months post transplant surgery (12 months)]</time_frame>
    <description>Time from transplant, free of antibody mediated rejection, defined as ISHLT grade AMR 1 or greater will be compared between the treatment groups. Hemodynamic compromise is defined as the need for inotropic agents due to a Cardiac Index (CI) &lt;2.0 L/min/m2 or a 25% decrease from baseline in addition to one of the following:&#xD;
Ejection fraction of &lt;40% or a 20% decrease from baseline, and the need for inotropic agents&#xD;
Fractional shortening of &lt;20% or a 25% decrease from baseline, and the need for inotropic agents</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Freedom from Hemodynamic Compromise Rejection in the Absence of a Biopsy or Histological Rejection Per Participant - by Treatment Group</measure>
    <time_frame>From transplant through 12 months post transplant surgery (12 months)</time_frame>
    <description>Time from transplant, free of antibody mediated rejection, defined as ISHLT grade AMR 1 or greater will be compared between the treatment groups</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Occurrence of Death - by Treatment Group</measure>
    <time_frame>From transplant through 12 months post transplant surgery (12 months)</time_frame>
    <description>Incidence of all-cause mortality will be compared between the treatment groups.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Occurrence of Re-Listed for Transplantation - by Treatment Group</measure>
    <time_frame>From transplant through 12 months post transplant surgery (12 months)</time_frame>
    <description>Incidence of participant(s) being re-listed for transplant will be compared between the treatment groups.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Occurrence of Re-Transplantation - by Treatment Group</measure>
    <time_frame>From transplant through 12 months post transplant surgery (12 months)]</time_frame>
    <description>Incidence of participant(s) re-transplantation will be compared between the treatment groups.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Acute Cellular Rejection (≥ International Society of Heart and Lung Transplantation (ISHLT) 2R) Per Patient - by Treatment Group</measure>
    <time_frame>From transplant through 12 months post transplant surgery (12 months)]</time_frame>
    <description>The frequency of events will be compared between the treatment groups.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Antibody Mediated Rejection (AMR) (≥ International Society of Heart and Lung Transplantation (ISHLT) AMR 1) Per Participant - by Treatment Group</measure>
    <time_frame>12 months post-transplantation</time_frame>
    <description>The frequency of events will be compared between the treatment groups.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Rejection Episodes Associated with Hemodynamic Compromise (HDC) Per Participant - by Treatment Group</measure>
    <time_frame>From transplant through 12 months post transplant surgery (12 months)]</time_frame>
    <description>The frequency of events will be compared between the treatment groups.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Intravascular Ultrasound (IVUS) Measurements From Baseline to 1 Year Post-Transplant- by Treatment Group</measure>
    <time_frame>Baseline (4 to 8 weeks post-transplant), 1 year post-transplant</time_frame>
    <description>Per protocol, per clinical research site standard of care.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Angiographic Evidence of Cardiac Allograft Vasculopathy (CAV) - by Treatment Group</measure>
    <time_frame>12 months post-transplantation</time_frame>
    <description>In accordance with the International Society of Heart and Lung Transplantation (ISHLT) Cardiac Allograft Vasculopathy (CAV) angiographic grading scale.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Participant Loss to follow up - by Treatment Group</measure>
    <time_frame>12 months post-transplantation</time_frame>
    <description>Incidence of participant loss to follow up will be compared between the treatment groups.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Occurrence of Serious Infections Requiring Intravenous Antimicrobial Therapy and Need for Hospitalization - by Treatment Group</measure>
    <time_frame>Through 24 months post transplant surgery</time_frame>
    <description>The frequency of serious infections requiring intravenous antimicrobial therapy and need for hospitalization will be compared between treatment groups.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of Tuberculosis - by Treatment Group</measure>
    <time_frame>Through 24 months post transplant surgery</time_frame>
    <description>The incidence of tuberculosis will be compared between treatment groups.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of Cytomegalovirus (CMV) Infection - by Treatment Group</measure>
    <time_frame>Through 24 months post transplant surgery</time_frame>
    <description>The incidence of CMV infection will be compared between treatment groups.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of Post-Transplant Lymphoproliferative Disease (PTLD) - by Treatment Group</measure>
    <time_frame>Through 24 months post transplant surgery</time_frame>
    <description>The incidence of PTLD will be compared between treatment groups.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Tolerability (Discontinuation of Study Drug) of Tocilizumab (TCZ) - by Treatment Group</measure>
    <time_frame>Through 24 months post transplant surgery</time_frame>
    <description>The number of participants who discontinue study drug, per protocol, will be compared between treatment groups.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">200</enrollment>
  <condition>Heart Transplant</condition>
  <arm_group>
    <arm_group_label>Tocilizumab + Standard of Care Triple IS</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Tocilizumab plus standard of care triple immunosuppression (IS). Heart transplant recipients will receive tocilizumab (Actemra®) plus standard triple maintenance immunosuppression.&#xD;
Standard of care triple maintenance immunosuppression includes:&#xD;
a calcineurin inhibitor (tacrolimus),&#xD;
an anti-proliferative treatment (mycophenolate mofetil) or Myfortic® (enteric-coated mycophenolate sodium), and&#xD;
steroids (methylprednisolone/prednisone) as prescribed by site physician investigator.&#xD;
Participants enrolled in the study will be followed for 24 months after their transplant surgery. Randomization will occur once a participant has weaned from cardiopulmonary bypass and has achieved hemodynamic stability without significant ongoing bleeding within the first 72 hours after transplant.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo + Standard of Care Triple IS</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo plus standard of care triple maintenance immunosuppression (IS). Heart transplant recipients will receive placebo plus standard triple maintenance immunosuppression.&#xD;
Standard of care triple maintenance immunosuppression includes:&#xD;
a calcineurin inhibitor (tacrolimus),&#xD;
an anti-proliferative treatment (mycophenolate mofetil) or Myfortic® (enteric-coated mycophenolate sodium), and&#xD;
steroids (methylprednisolone/prednisone) as prescribed by site physician investigator.&#xD;
Participants enrolled in the study will be followed for 24 months after their transplant surgery. Randomization will occur once a participant has weaned from cardiopulmonary bypass and has achieved hemodynamic stability without significant ongoing bleeding within the first 72 hours after transplant.</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>tocilizumab</intervention_name>
    <description>6 doses: 8mg/kg (maximum of 800 mg) given once every four weeks by intravenous infusion over a 20-week period, with a minimum of 21 days between each infusion.</description>
    <arm_group_label>Tocilizumab + Standard of Care Triple IS</arm_group_label>
    <other_name>Actemra®</other_name>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>The placebo is 0.9% sterile normal saline. 6 doses: 8mg/kg (maximum of 800 mg) given once every four weeks by intravenous infusion over a 20-week period, with a minimum of 21 days between each infusion.</description>
    <arm_group_label>Placebo + Standard of Care Triple IS</arm_group_label>
    <other_name>Placebo for tocilizumab</other_name>
    <other_name>Placebo for Actemra®</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Standard of Care Triple IS</intervention_name>
    <description>Standard of care triple maintenance IS includes:&#xD;
A calcineurin inhibitor-tacrolimus (Prograf ®) per site standards by sublingual, oral or intravenous route to attain target trough levels.&#xD;
Exception: Should a participant be unable to tolerate tacrolimus, the site physician investigator may choose cyclosporine treatment.&#xD;
An anti-proliferative treatment-mycophenolate mofetil or Myfortic® (enteric-coated mycophenolate sodium) will be administered, per protocol.&#xD;
Exception: Should a participant be unable to tolerate mycophenolate mofetil, the site physician investigator may choose an alternative treatment.&#xD;
Steroids-methylprednisolone/prednisone dosing will be given according to the local center standard of practice early post transplantation. After 6 months, prednisone may be withdrawn at the discretion of the site physician investigator, per protocol.</description>
    <arm_group_label>Placebo + Standard of Care Triple IS</arm_group_label>
    <arm_group_label>Tocilizumab + Standard of Care Triple IS</arm_group_label>
    <other_name>calcineurin inhibitor: (tacrolimus (Prograf ®))</other_name>
    <other_name>anti-proliferative treatment: (mycophenolate mofetil ),</other_name>
    <other_name>MMF, CellCept®</other_name>
    <other_name>Myfortic®, enteric-coated mycophenolate sodium</other_name>
    <other_name>steroids: methylprednisolone/prednisone</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
        Inclusion Criteria- Study Entry&#xD;
&#xD;
          1. Subject must be able to understand and provide informed consent;&#xD;
&#xD;
          2. Is a candidate for a primary heart transplant (listed as a heart transplant only);&#xD;
&#xD;
          3. No desensitization therapy prior to transplant;&#xD;
&#xD;
          4. Agreement to use contraception: according to the FDA Office of Women's Health&#xD;
             (http://www.fda.gov/birthcontrol), there are a number of birth control methods that&#xD;
             are more than 80% effective.&#xD;
&#xD;
               -  Female participants of child-bearing potential must consult with their physician&#xD;
                  and determine the most suitable method(s) from the above referenced list to be&#xD;
                  used for the duration of the study&#xD;
&#xD;
               -  Those who choose oral contraception must agree to use a second form of&#xD;
                  contraception after administration of study drug for a period of 1 year after the&#xD;
                  last dose of study drug.&#xD;
&#xD;
          5. Mechanical support or investigational drug trials where the intervention ends at the&#xD;
             time of transplantation are permitted;&#xD;
&#xD;
          6. In the absence of contraindication, vaccinations should be up to date for hepatitis B,&#xD;
             influenza, pneumococcal, zoster, and Measles, Mumps, &amp; Rubella (MMR); and&#xD;
&#xD;
          7. Subjects from areas of endemic coccidioidomycosis are eligible for inclusion but must&#xD;
             be treated prophylactically with fluconazole or itraconazole.&#xD;
&#xD;
        Inclusion Criteria - Randomization&#xD;
&#xD;
          1. Recipient of a primary heart transplant;&#xD;
&#xD;
          2. Negative virtual crossmatch (according to local center criteria);&#xD;
&#xD;
          3. No desensitization therapy prior to transplant;&#xD;
&#xD;
          4. Female subjects of childbearing potential must have a negative pregnancy test (serum&#xD;
             or urine) prior to randomization; and&#xD;
&#xD;
          5. Agreement to use contraception: according to the FDA Office of Women's Health&#xD;
             (http://www.fda.gov/birthcontrol), there are a number of birth control methods that&#xD;
             are more than 80% effective.&#xD;
&#xD;
               -  Female participants of child-bearing potential must consult with their physician&#xD;
                  and determine the most suitable method(s) from the above referenced list to be&#xD;
                  used for the duration of the study&#xD;
&#xD;
               -  Those who choose oral contraception must agree to use a second form of&#xD;
                  contraception after administration of study drug for a period of 1 year after the&#xD;
                  last dose of study drug.&#xD;
&#xD;
          6. Negative SARS-CoV-2 real-time reverse transcription polymerase chain reaction&#xD;
             (rRT-PCR) test result performed within 48 hours of transplant (SARS-CoV-2 is the virus&#xD;
             that causes COVID-19)&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
        Exclusion Criteria Study Entry&#xD;
&#xD;
          1. Inability or unwillingness of a participant to give written informed consent or comply&#xD;
             with study protocol;&#xD;
&#xD;
          2. Candidate for a multiple solid organ or tissue transplants;&#xD;
&#xD;
          3. Prior history of organ or cellular transplantation requiring ongoing systemic&#xD;
             immunosuppression;&#xD;
&#xD;
          4. Currently breast-feeding a child or plans to become pregnant during the timeframe of&#xD;
             the study follow up period;&#xD;
&#xD;
          5. History of severe allergic and/or anaphylactic reactions to humanized or murine&#xD;
             monoclonal antibodies;&#xD;
&#xD;
          6. Known hypersensitivity to tocilizumab (Actemra®);&#xD;
&#xD;
          7. Previous treatment with tocilizumab (Actemra®);&#xD;
&#xD;
          8. Human Immunodeficiency Virus (HIV) positive;&#xD;
&#xD;
          9. Hepatitis B surface antigen positive;&#xD;
&#xD;
         10. Hepatitis B core antibody positive;&#xD;
&#xD;
         11. Hepatitis C virus antibody positive (anti-HCV Ab+) who are either untreated or, have&#xD;
             failed to demonstrate sustained viral remission for more than 12 months (after&#xD;
             anti-viral treatment);&#xD;
&#xD;
         12. Recipient of a Hepatitis C virus nucleic acid test (NAT) positive donor organ;&#xD;
&#xD;
         13. Subjects must be tested for latent TB infection (LTBI) within a year prior to&#xD;
             transplant:&#xD;
&#xD;
             --Subjects with a positive test for LTBI must complete appropriate therapy for LTBI.&#xD;
&#xD;
             ---A Subject is considered eligible only if they have a negative test for LTBI within&#xD;
             one year prior to transplant OR&#xD;
&#xD;
             ---- if they have completed appropriate LTBI therapy within one year prior to&#xD;
             transplant.&#xD;
&#xD;
         14. Subjects with a previous history of active Tuberculosis (TB);&#xD;
&#xD;
         15. Subjects with a history of splenectomy;&#xD;
&#xD;
         16. Known active current viral, fungal, mycobacterial or other infections not including&#xD;
             (left ventricular assist device [LVAD]) driveline infections;&#xD;
&#xD;
         17. History of malignancy less than 5 years in remission.&#xD;
&#xD;
             --Any history of adequately treated in-situ cervical carcinoma, low grade prostate&#xD;
             carcinoma, or adequately treated basal or squamous cell carcinoma of the skin will be&#xD;
             permitted.&#xD;
&#xD;
         18. History of hemolytic-uremic syndrome/ thrombotic thrombocytopenia purpura;&#xD;
&#xD;
         19. History of demyelinating disorders such as:&#xD;
&#xD;
               -  multiple sclerosis,&#xD;
&#xD;
               -  chronic inflammation,&#xD;
&#xD;
               -  demyelinating polyneuropathy.&#xD;
&#xD;
         20. History of gastrointestinal perforations, active inflammatory bowel disease or&#xD;
             diverticulitis;&#xD;
&#xD;
         21. Any previous treatment with alkylating agents such as chlorambucil or, total lymphoid&#xD;
             irradiation;&#xD;
&#xD;
         22. Radiation therapy within 3 weeks before enrollment.&#xD;
&#xD;
             --Enrollment of subjects who require concurrent radiotherapy should be deferred until&#xD;
             the radiotherapy is completed and 3 weeks have elapsed since the last date of therapy.&#xD;
&#xD;
         23. Subjects with a hemoglobin &lt;7.0gm/dL (last measurement within 7 days prior to&#xD;
             transplant);&#xD;
&#xD;
         24. Subjects with a platelet count of less than 100,000/mm^3 (last measurement within 7&#xD;
             days prior to transplant);&#xD;
&#xD;
         25. Subjects with an absolute neutrophil count (ANC) of less than 2,000/mm^3 (last&#xD;
             measurement within 7 days prior to transplant);&#xD;
&#xD;
         26. Subjects with Aspartate Aminotransferase (AST) or Alanine Aminotransferase (ALT)&#xD;
             levels &gt;3 x Upper Limit of Normal (ULN);&#xD;
&#xD;
         27. Subjects who are administered or intended to be administered cytolytic or anti-cluster&#xD;
             of differentiation 25 (CD25) monoclonal antibody agents as induction therapy in the&#xD;
             immediate post-transplant period;&#xD;
&#xD;
         28. Intent to give the recipient a live vaccine within 30 days prior to randomization;&#xD;
&#xD;
         29. Past or current medical problems or findings from physical examination or laboratory&#xD;
             testing that are not listed above, which, in the opinion of the investigator, may:&#xD;
&#xD;
               -  pose additional risks from participation in the study,&#xD;
&#xD;
               -  may interfere with the participant's ability to comply with study requirements,&#xD;
                  or&#xD;
&#xD;
               -  that may impact the quality or interpretation of the data obtained from the&#xD;
                  study.&#xD;
&#xD;
        Exclusion Criteria - Randomization&#xD;
&#xD;
          1. Recipient of multiple solid organ or tissue transplants;&#xD;
&#xD;
          2. Recipient of ex vivo preserved hearts and hearts donated after cardiac death (DCD);&#xD;
&#xD;
          3. Currently breast-feeding a child or plans to become pregnant during the timeframe of&#xD;
             the study follow up period;&#xD;
&#xD;
          4. History of severe allergic anaphylactic reactions to humanized or murine monoclonal&#xD;
             antibodies;&#xD;
&#xD;
          5. Known hypersensitivity to tocilizumab (Actemra®);&#xD;
&#xD;
          6. Previous treatment with tocilizumab (Actemra®);&#xD;
&#xD;
          7. HIV positive;&#xD;
&#xD;
          8. Hepatitis B surface antigen positive;&#xD;
&#xD;
          9. Hepatitis B core antibody positive;&#xD;
&#xD;
         10. Hepatitis B negative transplant recipient that received a transplant from a hepatitis&#xD;
             B core antibody positive donor;&#xD;
&#xD;
         11. HCV+ subject(s) who are either untreated or have failed to demonstrate sustained viral&#xD;
             remission for more than 12 months after anti-viral treatment;&#xD;
&#xD;
         12. Recipient of a hepatitis C virus nucleic acid test (NAT) positive donor organ;&#xD;
&#xD;
         13. Subject's organ donor tests positive for SARS-CoV-2 by real-time reverse transcription&#xD;
             polymerase chain reaction (SARS-CoV-2 is the virus that causes COVID-19).&#xD;
&#xD;
         14. Subjects with a previous history of active (TB);&#xD;
&#xD;
         15. Subjects must be tested for latent TB infection (LTBI) within a year prior to&#xD;
             transplant:&#xD;
&#xD;
             --Subjects with a positive test for LTBI must complete appropriate therapy for LTBI.&#xD;
&#xD;
             ---A Subject is considered eligible only if they have a negative test for LTBI within&#xD;
             one year prior to transplant OR&#xD;
&#xD;
             ---- if they have completed appropriate LTBI therapy within one year prior to&#xD;
             transplant.&#xD;
&#xD;
         16. Subjects with a history of splenectomy;&#xD;
&#xD;
         17. Known active current viral, fungal, mycobacterial or other infections, not including&#xD;
             (left ventricular assist device [LVAD]) driveline infections;&#xD;
&#xD;
         18. History of malignancy less than 5 years in remission.&#xD;
&#xD;
             --Any history of adequately treated in-situ cervical carcinoma, low grade prostate&#xD;
             carcinoma, or adequately treated basal or squamous cell carcinoma of the skin will be&#xD;
             permitted.&#xD;
&#xD;
         19. History of hemolytic-uremic syndrome/ thrombotic thrombocytopenia purpura;&#xD;
&#xD;
         20. History of demyelinating disorders;&#xD;
&#xD;
         21. History of gastrointestinal perforations, active inflammatory bowel disease or&#xD;
             diverticulitis;&#xD;
&#xD;
         22. Any previous treatment with alkylating agents such as chlorambucil, or with total&#xD;
             lymphoid irradiation;&#xD;
&#xD;
         23. Radiation therapy within 3 weeks before randomization.&#xD;
&#xD;
             --Enrollment of subjects who require concurrent radiotherapy should be deferred until&#xD;
             the radiotherapy is completed and 3 weeks have elapsed since the last date of therapy.&#xD;
&#xD;
         24. Subjects with a hemoglobin &lt;7.0gm/dL within 7 days prior to randomization;&#xD;
&#xD;
         25. Subjects with a platelet count of less than 100,000/mm^3 within 7 days prior to&#xD;
             randomization;&#xD;
&#xD;
         26. Subjects with an absolute neutrophil count (ANC) of less than 2,000/mm^3 within 7 days&#xD;
             prior to randomization;&#xD;
&#xD;
         27. Subjects with AST or ALT levels &gt;3 x ULN;&#xD;
&#xD;
         28. Subjects who are administered or intended to be administered cytolytic or anti- CD25&#xD;
             monoclonal antibody agents as induction therapy in the immediate post- transplant&#xD;
             period;&#xD;
&#xD;
         29. Receipt of a live vaccine within 30 days prior to randomization;&#xD;
&#xD;
         30. Use of investigational drugs after transplantation;&#xD;
&#xD;
         31. Past or current medical problems or findings from physical examination or laboratory&#xD;
             testing that are not listed above, which, in the opinion of the investigator,&#xD;
&#xD;
               -  may pose additional risks from participation in the study,&#xD;
&#xD;
               -  may interfere with the participant's ability to comply with study requirements,&#xD;
                  or&#xD;
&#xD;
               -  that may impact the quality or interpretation of the data obtained from the&#xD;
                  study.&#xD;
&#xD;
         32. Subjects with known donor-specific antibody at the time of evaluation of antibodies&#xD;
             for heart transplant surgery (within 6 months).&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jon A. Kobashigawa, MD</last_name>
    <role>Study Chair</role>
    <affiliation>Cedars Sinai Medical Center: Transplantation</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Joren C. Madsen, MD, DPHIL</last_name>
    <role>Principal Investigator</role>
    <affiliation>Massachusetts General Hospital: Transplantation</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Cedars Sinai Medical Center (CACS)</name>
      <address>
        <city>Beverly Hills</city>
        <state>California</state>
        <zip>90211</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Olayiwola Babalola</last_name>
      <phone>310-248-8365</phone>
      <email>Olayiwola.babalola@csmns.org</email>
    </contact>
    <contact_backup>
      <last_name>Maria Thottam</last_name>
      <phone>310-248-7141</phone>
      <email>Maria.Thottam@cshs.org</email>
    </contact_backup>
    <investigator>
      <last_name>Jignesh Patel, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of California, San Diego: Sulpizio Cardiovascular Center (CASD)</name>
      <address>
        <city>La Jolla</city>
        <state>California</state>
        <zip>92037</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <investigator>
      <last_name>Eric D. Adler, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of California, Los Angeles (UCLA)</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90095</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Withdrawn</status>
  </location>
  <location>
    <facility>
      <name>Stanford Health Care (CASU)</name>
      <address>
        <city>Stanford</city>
        <state>California</state>
        <zip>94305</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Helen Luikart, RN</last_name>
      <phone>650-724-2883</phone>
      <email>luikart@stanford.edu</email>
    </contact>
    <contact_backup>
      <last_name>Julie Gordon</last_name>
      <phone>650-724-4740</phone>
      <email>Jgordon9@Stanford.edu</email>
    </contact_backup>
    <investigator>
      <last_name>Kiran K Khush, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Tampa General Hospital (FLTG)</name>
      <address>
        <city>Tampa</city>
        <state>Florida</state>
        <zip>33606</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Courtney Nicholas</last_name>
      <phone>813-844-4914</phone>
      <email>CourtneyLee@tgh.org</email>
    </contact>
    <investigator>
      <last_name>Luis Arroyo, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Northwestern Memorial Hospital (INLM)</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60611</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Dan Roshevsky, MS, CCRC</last_name>
      <phone>312-695-3264</phone>
      <email>droshevs@nm.org</email>
    </contact>
    <investigator>
      <last_name>Kambiz Ghafourian, MD, MPH</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Tufts Medical Center (MANM)</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02111</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Laura Telfer</last_name>
      <phone>617-636-4904</phone>
      <email>ltelfer@tuftsmedicalcenter.org</email>
    </contact>
    <investigator>
      <last_name>David DeNofrio, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Massachusetts General Hospital (MAMG)</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02114</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Mark Schoenike</last_name>
      <phone>713-249-1138</phone>
      <email>mschoenike@mgh.harvard.edu</email>
    </contact>
    <contact_backup>
      <last_name>Diane Cocca-Spofford</last_name>
      <phone>617-726-8228</phone>
      <email>Cocca-spofford.diane@mgh.harvard.edu</email>
    </contact_backup>
    <investigator>
      <last_name>Gregory Lewis, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>St. Luke's Hospital of Kansas City (MOLH)</name>
      <address>
        <city>Kansas City</city>
        <state>Missouri</state>
        <zip>64111</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Brenda Akers, RN</last_name>
      <phone>816-932-2779</phone>
      <email>bakers@saint-lukes.org</email>
    </contact>
    <contact_backup>
      <last_name>Karen Haffey, RN</last_name>
      <phone>816-932-2680</phone>
      <email>khaffey@saint-lukes.org</email>
    </contact_backup>
    <investigator>
      <last_name>Andrew Kao, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Nebraska Medical Center (NEUN)</name>
      <address>
        <city>Omaha</city>
        <state>Nebraska</state>
        <zip>68198</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Kimberly Shields, BSN, RN</last_name>
      <phone>402-559-0983</phone>
      <email>kimberly.shields@unmc.edu</email>
    </contact>
    <contact_backup>
      <last_name>Emily Schwindt, BSN, RN</last_name>
      <email>emily.schwindt@unmc.edu</email>
    </contact_backup>
    <investigator>
      <last_name>Brian Lowes, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Montefiore Medical Center (NYMA)</name>
      <address>
        <city>Bronx</city>
        <state>New York</state>
        <zip>10467</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Angeline Camilo</last_name>
      <phone>718-920-4595</phone>
      <email>acamilo@montefiore.org</email>
    </contact>
    <investigator>
      <last_name>Snehal R. Patel, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Mount Sinai Medical Center (NYMS)</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10029</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Adrianna Damato, CRC</last_name>
      <phone>212-241-1879</phone>
      <email>Adrianna.damato@mountsinai.org</email>
    </contact>
    <investigator>
      <last_name>Donna M. Mancini, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Columbia University Medical Center (NYCP)</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10032</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Andrea Kim</last_name>
      <phone>212-305-1368</phone>
      <email>AK451@cumc.columbia.edu</email>
    </contact>
    <investigator>
      <last_name>Maryjane A. Farr, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Duke University Medical Center (NCDU)</name>
      <address>
        <city>Durham</city>
        <state>North Carolina</state>
        <zip>27710</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Inneke Johnson</last_name>
      <phone>919-668-8222</phone>
      <email>lacey.taylor@duke.edu</email>
    </contact>
    <contact_backup>
      <last_name>Lacey Taylor</last_name>
      <phone>919-668-8222</phone>
      <email>lacey.taylor@duke.edu</email>
    </contact_backup>
    <investigator>
      <last_name>Chetan B. Patel, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Cleveland Clinic Foundation (OHCC)</name>
      <address>
        <city>Cleveland</city>
        <state>Ohio</state>
        <zip>44195</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Barbara Gus, RN BSN</last_name>
      <phone>216-445-6552</phone>
      <email>gusb@ccf.org</email>
    </contact>
    <contact_backup>
      <last_name>Lauren Ives, RN BSN</last_name>
      <phone>216-445-6552</phone>
      <email>IVESL@ccf.org</email>
    </contact_backup>
    <investigator>
      <last_name>Randall C. Starling, MD MPH</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Penn State Health: Milton S. Hershey Medical Center (PAHE)</name>
      <address>
        <city>Hershey</city>
        <state>Pennsylvania</state>
        <zip>17033</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Lisa Fox, RN</last_name>
      <phone>717-531-1468</phone>
      <email>LFox5@pennstatehealth.psu.edu</email>
    </contact>
    <contact_backup>
      <last_name>Kevin Gardner, RN,CCRC</last_name>
      <phone>717-531-6508</phone>
      <email>kgardner@pennstatehealth.psu.edu</email>
    </contact_backup>
    <investigator>
      <last_name>Howard J. Eisen, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hospital of the University of Pennsylvania (PAUP)</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19104</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Nicole Escobar</last_name>
      <phone>215-662-4214</phone>
      <email>Nicole.Escobar@pennmedicine.upenn.edu</email>
    </contact>
    <contact_backup>
      <last_name>Tiffany Sharkoski</last_name>
      <phone>215-662-4214</phone>
      <email>Tiffany.Sharkoski@pennmedicine.upenn.edu</email>
    </contact_backup>
    <investigator>
      <last_name>Lee Goldberg, MD PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Allegheny General Hospital (PAAG)</name>
      <address>
        <city>Pittsburgh</city>
        <state>Pennsylvania</state>
        <zip>15212</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Laurie Machen</last_name>
      <phone>412-359-6181</phone>
      <email>Laurie.Machen@ahn.org</email>
    </contact>
    <investigator>
      <last_name>Srinivas Murali, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Vanderbilt University Medical Center (TNVU)</name>
      <address>
        <city>Nashville</city>
        <state>Tennessee</state>
        <zip>37232</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Kathy Adams</last_name>
      <phone>615-322-9845</phone>
      <email>kathy.adams@vumc.org</email>
    </contact>
    <investigator>
      <last_name>Kelly H. Schlendorf, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Baylor University Medical Center (TXTX)</name>
      <address>
        <city>Dallas</city>
        <state>Texas</state>
        <zip>75246</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Michelle Clark</last_name>
      <phone>214-820-1685</phone>
      <email>Donna.Clark1@BSWHealth.org</email>
    </contact>
    <contact_backup>
      <last_name>Amanda Doss, BS</last_name>
      <phone>214-820-1685</phone>
      <email>Amanda.Doss@BSWHealth.org</email>
    </contact_backup>
    <investigator>
      <last_name>Shelley Hall, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Utah (UTMC)</name>
      <address>
        <city>Salt Lake City</city>
        <state>Utah</state>
        <zip>84132</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Habeeb Mohammad</last_name>
      <phone>801-587-4880</phone>
      <email>Habeeb.mohammad@hsc.utah.edu</email>
    </contact>
    <contact_backup>
      <last_name>Mija Wall</last_name>
      <email>Mija.Wall@hsc.utah.edu</email>
    </contact_backup>
    <investigator>
      <last_name>Josef Stehlik, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Washington Medical Center (WAUW)</name>
      <address>
        <city>Seattle</city>
        <state>Washington</state>
        <zip>98195</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Withdrawn</status>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>https://www.niaid.nih.gov/</url>
    <description>National Institute of Allergy and Infectious Diseases (NIAID)</description>
  </link>
  <link>
    <url>https://www.niaid.nih.gov/about/dait</url>
    <description>The Division of Allergy, Immunology, and Transplantation (DAIT)</description>
  </link>
  <verification_date>March 2021</verification_date>
  <study_first_submitted>August 21, 2018</study_first_submitted>
  <study_first_submitted_qc>August 22, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">August 23, 2018</study_first_posted>
  <last_update_submitted>March 12, 2021</last_update_submitted>
  <last_update_submitted_qc>March 12, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">March 16, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>heart transplant recipients</keyword>
  <keyword>alloimmunity</keyword>
  <keyword>anti-inflammatory</keyword>
  <keyword>tocilizumab</keyword>
  <keyword>efficacy clinical trial</keyword>
  <keyword>immunosuppression (IS)</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Mycophenolic Acid</mesh_term>
    <mesh_term>Prednisone</mesh_term>
    <mesh_term>Methylprednisolone</mesh_term>
    <mesh_term>Tacrolimus</mesh_term>
    <mesh_term>Calcineurin Inhibitors</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

